A simple and direct plaque assay for maedi virus, two strains of progressive pneumonia virus, and two strains of visna virus has been developed and evaluated. The technique allows the plaques formed by these viruses to be localized without disturbing the host-cell substrate of sheep choroid plexus cells or the gelled maintenance medium over the host-cell monolayer. Diethylaminoethyl-dextran supplementation of the medium used to overlay strain K796 visna virus-infected cultures decreases the time required for maximum plaque development from 12 to 10 days, enhances the contrast of the plaques, increases the titer of plaque-forming units, and permits a plaque size heterogeneity to be realized. Both large and small plaques occur in cultures infected with the visna viruses, one strain of progressive pneumonia virus, or maedi virus. In contrast, the plaques observed in cultures infected with the second strain of progressive pneumonia virus are relatively homogeneous in size.
The viruses of visna, maedi, and progressive pneumonia are the cause of disease in sheep, characterized by paresis and/or dypsnea which ultimately and irreversibly progresses to the natural host's death (5, 6, (8) (9) (10) (11) 20 ; N. G. Rogers et al., Bacteriol. Proc., p. 181, 1971). The studies with these viruses have been dependent upon an end-point assay which determined the amount of virus capable of producing a cytopathic effect in most of the cells within 14 to 21 days after infection of the host-cell population. The end points obtained depend not only upon the amount of virus present but also have been stated to depend on both the strain and the passage level of the cells (6, 16, 19) . These facts complicate studies of the host-virus interaction. Additionally, these viruses have not been subjected to procedures which would allow genetically pure lines of virus to be obtained.
Plaque formation by visna virus has been reported by Harter (3) and by Harter and Choppin (4) to require 11 to 14 days. Visualization of the visna virus-induced plaques involves either fixing and staining the host-cell substrate or adding a secondary cellular overlay to the virus-infected host cell monolayer. The number of visna virus-specific plaque-forming units obtained by the former method was found to be 2.5-fold greater than the number of tissue culture infective units obtained by end-point titration (3) . In contrast, Lopez, Eklund, and Hadlow found the titer of progressive pneumonia virus obtained by this plaque assay to be 361 one-tenth the titer obtained by end-point titration (6) . The use of a secondary cellular overlay composed of cells which are fused and killed by visna virus, but which do not support virus synthesis, will not detect a virus incapable of causing cell fusion or plaques containing relatively little progeny virus.
Subsequent reports note the use of plaque assays for both visna virus and progressive pneumonia virus, and the plaque purification of these viruses (2, 12, 13, 14) . These reports do not describe the assay or demonstrate that it satisfies the criteria enumerated by P. D. Cooper for the assay to be useful (1) . Additionally, plaque formation by a second strain of progressive pneumonia virus and by maedi virus has not been reported to occur.
This report describes and evaluates a relatively simple and efficient plaque assay for five members of the maedi-progressive pneumoniavisna virus group.
MATERIALS AND METHODS Cells. The choroid plexus was aseptically removed from the brains of recently slaughtered lambs and transferred to and minced in a petri dish containing several milliliters of growth medium (GM). The GM consisted of 86 parts of Eagle basal medium with Earle salts containing 100 units of penicillin per ml, 100 lgg of streptomycin per ml, 0.375 g of sodium bicarbonate per liter, 200 mM L-glutamine, and 14 parts of lamb serum (Colorado Serum Company, Denver, Colo.). The medium without the serum is referred to as BME. The minced choroid plexus was rinsed with several changes of GM to remove the adherent blood, suspended in 2 ml of GM, transferred to a 25-cm2 plastic flask, and incubated at 37 C until the tissue attached to the vessel's surface (2 days). An additional 3.0 ml of GM was then added to each vessel and the cultures were reincubated at 37 C. A monolayer of confluent fibroblastic sheep choroid plexus (SCP) cells was present within 10 days after the tissue was explanted. These cells were dispersed with and suspended in a 0.1% solution of trypsin in BME. The resulting cell suspension was transferred to a 250-ml flask containing 25 ml of GM and incubated for 5 to 6 days at 37 C. This transfer represented passage number one. The confluent cells were then trypsinized, transferred to, and routinely propagated in 32-oz prescription bottles. Each bottle was seeded with 2 x 106 to 3 x 106 SCP cells, and the cells were fed 50 ml of GM and harvested 3 or 4 days later when the number of cells was 1.5 x 107 to 3.0 x 107 per 32-oz bottle. SCP cells from different choroid plexi were considered different strains.
Low passage-level cells of the individual strains were frozen in 1.0-ml ampules at a cell density of 106 to 2 x 106 cells per ml of GM supplemented with 10% (vol/vol) glycerol and stored in liquid nitrogen. The cells in these ampules were rapidly thawed in a 37 C water bath, transferred to a 250-ml plastic flask, fed 25 ml of GM, and incubated at 37 C. The medium was completely changed 24 h later. The cells from such ampules became confluent within 10 Assay of infectious virus. Cultures of confluent SCP cells in 21-cm2 plastic petri dishes were prepared for the plaque assay by being initiated with 3.5 x 101 to 4.0 x 105 SCP cells in 5.0 ml of GM. The cells in these cultures were confluent and were routinely used for the plaque assay 3 days after being initiated and incubated at 37 C in a humidified atmosphere containing 5% C02. The GM was removed from and 1.0 ml of serial dilutions of virus was added to each culture. Virus was diluted in cold MM. Adsorption of virus was allowed to occur for 2 h at 37 C. The virus inoculum was redistributed over the monolayer at half-hour intervals during the 2-h viral-adsorption period.
The cell sheet was then overlaid with 5.0 ml of plaque medium (PM). The 1.0 ml of diluted virus inoculum and the PM were thoroughly mixed as the PM was being added to each culture. This PM consisted of double-strength BME without phenol red supplemented with 0.4% bovine serum albumin, mycostatin (200 units/ml), and an additional 1.125 g of sodium bicarbonate per liter mixed with an equal volume of 1% agarose (Fisher Scientific Co., Cat. #J-24040-S). The agarose was suspended in sterile deionized water and sterilized in a boiling water bath for 1 h prior to being used in the plaque assay. The sterilized agarose was stored at 4 C and was not used for this initial overlay if it had been remelted more than once. After the PM in the plate cultures had solidified, the cultures were reincubated at 37 C in humidified air containing 5% C02. A 2.5-ml feeder layer of PM was added to the initial PM overlay on the tenth postinfection day in cultures infected with G-PPV or maedi virus.
A 2-ml amount of PM containing 1: 10,000 (wt/vol) neutral red was added to the cultures at various times after they were infected. The viable cells incorporated a sufficient amount of neutral red for the plaques to be observed within 4 to 6 h of incubation at 37 C.
Visualization of the plaques was enhanced by viewing the stained monolayer against an evenly illuminated background covered with a transparent medium blue-green filter (Edmund Scientific Co., Barrington, N.J., Cat. #82,042).
Infective strain K796 visna virus titers were also determined by the 50% end-point method described by Thormar (15 (Table 1) . Dextran sulfate was also found to dramatically decrease the plaqueforming titer when it was added to the PM used to overlay the virus-infected SCP cell monolayer (Table 1 ). In contrast, DEAE-dextran increased the titer of visna virus and improved the contrast between the plaque and its surrounding cells when this polycation was added to the PM (Table 1 and Fig. 1 ). There was also a more noticeable heterogeneity of plaque size in monolayers overlaid with PM containing DEAE-dextran than in monolayers overlaid with PM not containing DEAE-dextran.
The addition of DEAE-dextran to the PM was also found to decrease the time required for maximum plaque development ( Table 2 ). The plaque number in monolayers infected with approximately 60 PFU and overlaid with PM was less than that observed in similar cultures overlaid with PM containing DEAE-dextran when these cultures were stained and the plaques enumerated on the 9th, 10th, and 11th days after infection. The number of plaques in those cultures overlaid with PM containing either no DEAE-dextran or 5 pg of this polycation per ml was one-fifth to one-half of the number of plaques observed in those cultures overlaid with PM containing 10 or 15 ,ug of this polycation per ml of PM. The number of plaques in the cultures overlaid with PM not supplemented with DEAE-dextran increased fivefold from the 9th to the 12th day after infection. In contrast, the number of plaques in the cultures overlaid with PM containing 5 ,ug of this polycation increased only twofold during this interval. Similarly, the number of plaques observed on the 11th day in cultures overlaid with PM containing 10 or 15 ,g of DEAE-dextran was only 1.1-fold greater than the 9-day value.
These results show that DEAE-dextran, at a concentration of 10 or 15 ug of PM per ml, increased the eop by visna virus. Additionally, the presence of this polycation decreased the time required for maximum plaque development from greater than 12 days to 10 days. The plaques in those cultures overlaid with PM containing DEAE-dextran began to coalesce on the 11th day after infection. The decrease in the number of plaques observed in these cultures on the 12th day was therefore due to plaque overlap. The diameter of the plaques observed on the 10th day postinfection in visna virusinfected cultures ranged from 0.9 to 5.4 mm with an average diameter of 3. A plaque size heterogeneity was observed in cultures infected with strain K485 visna virus, strain K796 visna virus, T-PPV, and maedi virus ( Fig. 1 and 2) , whereas the size of plaques in G-PPV-infected cultures was relatively more homogeneous (Fig. 2) .
Evaluation of the plaque assay. This plaque assay's utility was demonstrated by the existence of a linear relationship between relative virus concentration and plaque number ( Table TABLE 3 . Time of maximum plaque formation in cultures infected with strain K485 visna virus, maedi virus, T-PPV, or G-PPV and overlaid with PM supplemented with DEAE-dextran Mean plaque no. on postinfection daya 7  8  9  10  11  12  13  14  16  18  20   T-PPV  28  41  75  96  96   K485 p8   11  27  56  62  84  75  K485 p41   13  18  23  35  34  34  Maedi  45  52  50  52  G-PPV  6  37  72  60 a Values are the mean number of plaques per plate obtained from three plates for each postinfection day. 4) , by the absence of plaques in uninfected cultures, by the presence of 1,000 to 2,000 PFU in the plaque's center and the absence of detectable virus (less than 40 PFU) 8 mm from the plaque's center, by plaque-formation not occurring when strain K796 visna virus-infected cultures were overlaid with.,PM containing antiserum, and by the cell passage level not affecting the titer of plaque-forming units in a preserved visna virus stock (Table 5 ) (1). The sensitivity and the reproducibility of the plaque assay and of the end-point assay were compared. One stock of strain K796 visna virus was assayed by plaque technique on one strain of SCP cells over a 5-month period. This same strain of cells at the 11th and at the 12th passage level was used to determine the TCID5O titer. Twenty tube cultures were used for each 10-fold dilution of virus. Tissue culture infectious units (TCIU) were obtained by multiplying the TCID5O titers by 0.69. The mean number of PFU per milliliter was 1.5 x 107 and the standard deviation was 2.7 x 106 ( Table 5 ). The mean number of TCIU per milliliter was 2.8 x 106 and the standard deviation was 1.4 x 106. The PFU: TCIU ratio was 5.4. These results show that the plaque assay is a more sensitive and a more reproducible indicator of visna virus infectivity than is the end-point assay.
Three different strains of SCP cells were used to assay one strain K796 visna virus stock to determine the differences in susceptibility of these SCP cell strains to visna virus-induced plaque formation (Table 6) . Two of the three tested cell strains yielded equivalent PFU titers which were 10 times the titer obtained on the third cell strain. DISCUSSION The present work shows that SCP cells incorporate neutral red and that the plaques produced on SCP cell monolayers by five members of the maedi-progressive pneumonia-visna virus complex can be detected with the aid of this vital stain. Incorporation of the polycation, DEAE-dextran, into the plaque medium enhances the contrast between the plaques and their peripheral viable cells, increases the apparent efficiency of plaque formation, decreases the time required for plaque formation by visna virus, and results in a plaque size heterogeneity being observed in cultures infected with maedi virus, visna virus, and one strain of PPV. The enhancing effect of DEAE-dextran and the inhibitory effect of dextran sulfate (Table 1) when these polyions are present in the plaque medium indicates that the agarose contains sulfated polysaccharides which are counteracted in their effects by the polycation. These results are in accord with the observation by Harter (3) of visna virus having a higher eop on monolayers maintained under medium containing carboxymethylcellulose than in cells overlaid with medium containing either agar or agarose.
The finding that the eop of visna virus may vary from one SCP cell strain to another (Table  6) demonstrates that all strains of SCP cells are not equally suitable for use in the plaque assay and dictates that a comparison of the eop of visna virus on several cell strains must be made before any one cell strain is used for the assay.
The visna virus titer obtained on high passage level cells, on cells which had been subjected to storage in liquid nitrogen, and on low passage level cells was found to not be significantly different (Table 5) . Therefore, cells of those strains which serve as a suitable host substrate in the plaque assay, as evidenced by yielding a comparatively high visna virus eop, may be frozen and stored in liquid nitrogen for future use in the plaque assay.
The finding that the plaque-forming titer of a given visna virus sample is fivefold greater than the titer of TCIU indicates that infection of a culture requires at least five infectious particles for the culture to be scored as infected 14 aPlaque-forming units per milliliter obtained from the mean of the number of plaques from three plates.
h Standard deviation. Mean titer for 9 assays = 1.5 x 10' PFU/ml; standard deviation = 2.7 x 106; coefficient of variation = 17.6%. organ of virus origin, or its in vitro passage level. Additionally, the virus' organ and country of origin do not determine the morphology of the plaques produced by a particular virus. This plaque assay should allow investigators to determine if these viruses are biologically different.
